Tivozanib

(Fotivda)

Tivozanib

Drug updated on 11/15/2023

Dosage FormCapsule (oral; 1.34 mg, 0.89 mg)
Drug ClassKinase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.